4-MeO-MiPT

Use and effects

Shulgin found the effective dose to be 20 to 30mg (or ~0.4mg/kg body weight of subject) orally; the onset between ingestion and the first noticeable effects was 20 to 40minutes, with a listed duration of 4 to 6hours. The effects were significantly milder than those of 4-HO-MiPT, with 4-MeO-MiPT producing erotic-enhancing effects, and few of the visuals common with tryptamines. Online anecdotal reports describe 4-MeO-MiPT as producing mild psychedelic effects with little body load.

Interactions

Pharmacology

Pharmacodynamics

4-MeO-MiPT acts as a serotonin reuptake inhibitor (SRI) and non-selective serotonin receptor agonist, including of the serotonin 5-HT1A, 5-HT2A, 5-HT2C receptors. Affinities towards receptors outside of the serotonin receptor family have not yet been assessed.

Increased extracellular concentrations of serotonin, resulting from SERT blockade, similarly may compete at the serotonin 5-HT2A receptor, altering or blunting effects mediated by this receptor, which could potentially explain anecdotal reports of subjective effects being dose-dependently milder than that of 4-HO-MiPT or 5-MeO-MiPT. This profile makes 4-MeO-MiPT a potential candidate for elucidating the role of SERT blockade in the mechanisms underlying serotonergic psychedelic action.

The drug induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. Its potency for inducing the head-twitch response in mice is similar to that of 4-HO-MiPT and 4-AcO-MiPT, but the efficacy for doing so is markedly lower: 34 head twitches versus around 80 head twitches per 30minutes for the aforementioned compounds.

Chemistry

4-MeO-MiPT is synthetic derivative of the substituted tryptamine and 4-methoxytryptamine families. It is the 4-methoxy analogue of N-methyl-N-isopropyltryptamine (MiPT) and the O-methyl ether of 4-HO-MiPT.

Synthesis

The chemical synthesis of 4-MeO-MiPT has been described.

Analogues

Analogues of 4-MeO-MiPT include N-methyl-N-isopropyltryptamine (MiPT), 4-methoxytryptamine (4-MeO-T), 4-MeO-DiPT, 4-MeO-DMT, 4-HO-MiPT, 4-AcO-MiPT, 5-MeO-MiPT, 5-MeO-DMT, and psilocin (4-HO-DMT), among others.

History

4-MeO-MiPT was first described in the scientific literature by David Repke and Alexander Shulgin and colleagues in 1985. Subsequently, it was described in greater detail by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known Loved) as entry #39. The pharmacology of 4-MeO-MiPT was studied and described in the 2020s. It was reported as a novel designer drug by at least 2016.

Society and culture

Legal status

Canada

4-MeO-MiPT is not an explicitly nor implicitly controlled substance in Canada as of 2025.

United States

4-MeO-MiPT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

References

References

1. {{CiteTiHKAL http://www.erowid.org/library/books_online/tihkal/tihkal39.shtml
2. "4-MeO-MIPT (4-MeOMiPT)".
3. (July 1985). "Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents". Journal of Medicinal Chemistry.
4. (April 2023). "Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)_2A Receptor (5-HT_2AR), 5-HT_2CR, 5-HT_1AR, and Serotonin Transporter". The Journal of Pharmacology and Experimental Therapeutics.
5. (2024-06-01). "Pharmacological profiles and psychedelic-like effects of 4-hydroxy-, 4-acetoxy-, and 4-methoxy-N- methyl- N- isopropyltryptamine". The Journal of Pharmacology and Experimental Therapeutics.
6. (2016). "Test purchase of new synthetic tryptamines via the Internet: Identity check by GC-MS and separation by HPLC". Journal of Applied Pharmaceutical Science.
7. (5 December 2025). "Controlled Drugs and Substances Act".
8. (January 2026). "Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)". U.S. [[Department of Justice]]: [[Drug Enforcement Administration]] (DEA): Diversion Control Division.